Raymond James raised the firm's price target on Dianthus to $125 from $123 and keeps a Strong Buy rating on the shares. Dianthus' Q1 update highlighted pipeline progress including prioritized indications for DNTH212 supported by its dual BDCA2 and BAFF/APRIL mechanism, orphan drug designation for claseprubart in gMG, and multiple near-term catalysts including Phase 1 data in 2H26, a Phase 2 readout in MMN in Q4, and planned Phase 3 initiation in mid-2026 with topline results expected in 2H28, the analyst tells investors in a research note.
